Assessment of Cardiac Function, Microvascular Function and Cardiac Perfusion in Different Disease Stages of Hypertrophic Cardiomyopathy

NCT06400524 | Recruiting DMC

• 1 other identifier: NL83573.018.23
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by asymmetric hypertrophy of the heart in absence of loading conditions like hypertension. The genetic mutation underlying HCM sets in motion a cascade of functional and metabolic changes ultimately leading to disease. HCM patients often have microvascular dysfunction and myocardial perfusion deficits, of which the aetiology has not been elucidated. Whether these changes are secondary to remodelling or primarily caused by endothelial dysfunction is unclear. As the pathomechanism of HCM is thought to be a cascade of changes, it is important to gain more insight in the perfusion and endothelial function changes throughout different stages of disease: no phenotype, mild phenotype, and advanced HCM phenotype. In this study we aim to investigate these changes in the two most common genetic mutations.

Conditions

Hypertrophic Cardiomyopathy; Hypertrophic Cardiomyopathy, Obstructive

Keywords

hypertrophic cardiomyopathy; perfusion; endothelial function

Outcome Measures

Primary Outcomes (2)

• myocardial blood flow

  assessed by PET and CMR

  1 month

• peripheral endothelial function

  assessed by EndoPAT and LASCA

  1 month

Secondary Outcomes (3)

• Tissue characterization

  1 month

• Diastolic dysfunction

  1 month

• Fibrosis

  1 month

Study Arms (4)

Healthy controls

Mutation carriers

Mild hypertrophy

Overt hypertrophy

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Potential study subjects are recruited from different hospitals and will be invited to the VUmc. Our research consortium consists of cardiologists and cardiogeneticists who will spread our call for participants to their patients. We will also work together with the HCM patient organization. Potential study subjects will be invited to contact us by phone or e-mail, after which an information letter will be sent. If someone is interested in participation in the study, they will be invited to the VUmc to sign informed consent and undergo day 1 of the study.

You may qualify if:

• One of below:
• MYBPC3 mutation carrier
• MYH7 mutation carrier
• Genotype-negative first degree relative of a MYBPC3 or MYH7 mutation carrier
• All of the following criteria:
• For the mutation carrier group: ≥18 years old
• For the genotype-negative group: ≥30 years old
• MYBPC3 and MYH7 mutation carriers will be designated to one of three groups based on their maximum wall thickness, measured by echocardiography and MRI:
• No phenotype: MWT \<12mm
• Mild Phenotype: MWT ≥12 until \<15mm
• HCM phenotype: MWT ≥15mm

You may not qualify if:

• ≥70 years old
• Insulin-dependent diabetes mellitus
• Pregnancy
• Smoking
• Claustrophobia
• Pacemaker/ICD
• Renal insufficiency \<30 GFR
• Hypertension (systolic \>140mmHg or diastolic \>90mmHg)
• For the genotype negative group, no phenotype group, and mild phenotype group: the use of blood pressure medication (diuretics, beta-blockers, ACE-inhibitors, angiotensin II receptor blockers, calcium channel blockers, alpha blockers)
• For the HCM phenotype group: when it is unsafe to withhold from blood pressure medication (as specified above) for two days, as assessed by their own cardiologist
• Left ventricular outflow tract gradient \> 50mmHg
• Aortic valve disease
• Left bundle branch block
• (History of) Obstructive coronary artery disease
• Chronic atrial fibrillation

Sponsors & Collaborators

• Amsterdam UMC, location VUmc: lead

Study Sites (1)

Amsterdam UMC - location VUmc

Amsterdam, North Holland, 1081HV, Netherlands

RECRUITING

MeSH Terms

Conditions

Cardiomyopathy, Hypertrophic

Condition Hierarchy (Ancestors)

Cardiomyopathies; Heart Diseases; Cardiovascular Diseases; Aortic Stenosis, Subvalvular; Aortic Valve Stenosis; Aortic Valve Disease; Heart Valve Diseases

Central Study Contacts

Julia E Visch, MD

CONTACT

+31629349699; j.visch@amsterdamumc.nl

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr.

Study Record Dates

• First Submitted: May 1, 2024
• First Posted: May 6, 2024
• Study Start: May 1, 2024
• Primary Completion: May 1, 2026
• Study Completion: May 1, 2026
• Last Updated: May 6, 2024

Record last verified: 2024-05

Locations

NL (1)